It compares two approved types of digital mammography: standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). 2-D mammography takes pictures from two angles of the breast to create a flat image. 3-D mammography images are taken from multiple angles around the breast and then reconstructed into a 3-D-like image.

The goal of breast cancer screening is to find breast cancer early when it may be easier to treat. The TMIST trial aims to find out whether the newer technology is more effective than conventional 2-D mammography at reducing life-threatening (advanced) breast cancers.

The TMIST Lead-In study, led by Dr. Paula Gordon at the Breast Health Centre at C&W and Dr. Linda Warren at X-Ray 505, is now in its follow up stages with one-third of the 306 study participants completing their final screen to date. This Lead-In study has been funded by The Diamond Family.

Another important aspect of the trial is to build a tissue bank for future research. All women who joined the trial have been asked to submit tissue samples, such as blood and cheek swabs.  Researchers hope that the information from these tissue samples will help decide the best ways to screen for breast cancer in the future by taking a person’s genetics and other personal risk factors into account. Currently we have collected bio-specimens from approximately 25% of the participants.

With the success of the Lead-In study, we are nearly ready to begin recruitment on the main TMIST study. Women ages 45 to 74 who are planning to get a routine screening mammogram are eligible for this trial. The main study will be funded by the NIH.

If you would like to participate, or would like further information on participating, please contact the research team at TMIST@cw.bc.ca